TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33981386
Drug: Intravenous acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous acetaminophen plus 0.1 mg/kg ondansetron intravenously
Study: 33981386
Drug: Intravenous acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous acetaminophen plus 2 ml of normal saline intravenously
Study: 32671667
Drug: Baseline GFR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline GFR > 60 mL/min/1.73 m2
Study: 32671667
Drug: Baseline GFR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline GFR < 60 mL/min/1.73 m2
Study: 33158765
Drug: Nivolumab with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab with chemotherapy (≤ 4 cycles of platinum-based chemotherapy with pemetrexed + nivolumab for ≤ 12 cycles as maintenance)
Study: 33158765
Drug: Nivolumab with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab with chemotherapy
Study: 33158765
Drug: Chemotherapy (≤
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (≤ 4 cycles of platinum-based chemotherapy with pemetrexed)
Study: 32940628
Drug: nab-paclitaxel, 260
Approvals — FDA: no, EMA: no, PMDA: no
Description: nab-paclitaxel, 260 mg/m2 every 3 weeks
Study: 32940628
Drug: paclitaxel, 175
Approvals — FDA: no, EMA: no, PMDA: no
Description: paclitaxel, 175 mg/m2 every 3 weeks
Study: 34903431
Drug: Pelvic radiotherapy
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic radiotherapy with concurrent chemoradiotherapy followed by adjuvant chemotherapy
Study: 35276486
Drug: Melatonin 36
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 36 mg (Mel 36 group; n=6)
Study: 35276486
Drug: Melatonin 18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 18 mg (Mel 18 group; n=6)
Study: 33246338
Drug: C-reactive protein
Normalized name: C-reactive protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-reactive protein (3-10 mg/L)
Study: 33295007
Drug: Apalutamide +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apalutamide + androgen deprivation therapy
Study: 33295007
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + androgen deprivation therapy
Study: 32825070
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of smart gamification and financial rewards
Study: 33061332
Drug: Intensified postoperative
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensified postoperative physical therapy treatment including daily supervised early mobilization and coached deep breathing exercises with positive expiratory pressure (PEP)
Study: 34997449
Drug: FTD/TPI 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTD/TPI 35 mg/m2
Study: 33762689
Drug: Bifidobacterium longum
Normalized name: Bifidobacterium longum
DrugBank: Bifidobacterium longum (DB19248)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifidobacterium longum subsp. infantis (B. infantis) EVC001 (EVC) daily for 21 days
Study: 35321558
Drug: Non-RAS inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-RAS inhibitors (calcium channel blockers and diuretics)
Study: 35321558
Drug: RAS inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAS inhibitors (ACE inhibitors, ARBs, and β-blockers)
Study: 35321558
Drug: Baseline RAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline RAS inhibitor or non-inhibitor treatments
Study: 32968290
Drug: Self-medication practices
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-medication practices
Study: 34907064
Drug: Physiotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiotherapy and cognitive behavioural therapy (CBT) for 9 weeks each
Study: 34657055
Drug: Regorafenib (Rego)
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib (Rego) 160 mg/kg body weight orally every 28 days for 21 days
Study: 34657055
Drug: S-1 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 plus Bevacizumab (SB), S-1 orally every 42 days for 28 days and Bev 5 mg/kg intravenously on days 1, 15, and 29
Study: 33369354
Drug: Focused ultrasound
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focused ultrasound subthalamotomy (active treatment)
Study: 34924287
Drug: GnRHa supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRHa supplementation (two boluses of triptorelin 0.1 mg)
Study: 32598098
Drug: 40% hydrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40% hydrogen peroxide (bleaching agent)
Study: 32598098
Drug: 35% carbamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35% carbamide peroxide (bleaching agent)
Study: 35315627
Drug: Perioperative cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative cognitive therapy combined with rehabilitation exercise
Study: 33793078
Drug: Oat consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oat consumption (80 g oats containing 3 g beta-glucan daily for 45 days)
Study: 34815362
Drug: Doubling the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doubling the retesting rate within 4 months of treatment
Study: 34815362
Drug: Increasing partner
Normalized name: Milkthistle Fruit (Silybum Marianum L. Gaertner)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing partner treatment rate from 30% to 50%
Study: 36180944
Drug: Best established
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best established treatment only (BET)
Study: 33761679
Drug: Tanreqing injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tanreqing injection combined with azithromycin
Study: 33415857
Drug: Neurology treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurology treatment
Study: 35617104
Drug: Treosulfan (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treosulfan (30 g/m2 IV)
Study: 35617104
Drug: Busulfan (6.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Busulfan (6.4 mg/kg IV)
Study: 34145306
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (mitotoxic antibiotic without supplementation)
Study: 32195962
Drug: Tablet computer-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet computer-based cognitive training program (30 minutes per session, twice a week for 12 weeks)
Study: 32195962
Drug: Tablet computer-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet computer-based cognitive training program
Study: 33909260
Drug: Shuanghuanglian (SHL)
Normalized name: TRACH CANNULA,SZ 10 SHLY #10IC10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shuanghuanglian (SHL) treatment (14-day treatment)
Study: 33909260
Drug: High-dose Shuanghuanglian
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Shuanghuanglian (SHL) treatment
Study: 35524205
Drug: Camrelizumab plus
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camrelizumab plus chemotherapy (IO-CT)
Study: 32780660
Drug: Brigatinib 180
Normalized name: brigatinib 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brigatinib 180 mg once daily (7-day lead-in at 90 mg once daily)
Study: 33766695
Drug: Structured hypertension
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured hypertension education program (once weekly education session for 4 weeks, home blood pressure monitoring, dose changes in antihypertensives)
Study: 35113805
Drug: AZD4017 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD4017 (400 mg oral, bi-daily for 35 days)
Study: 33152538
Drug: Concurrent systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent systemic antibiotics at catheter insertion
Study: 33152538
Drug: No antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotics at catheter insertion
Study: 36105248
Drug: Antithrombotic elastic
Normalized name: elastin
DrugBank: Elastin (human) (DB15364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombotic elastic socks combined with pneumatic treatment intervention
Study: 32300579
Drug: Intravenous ACBMNC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ACBMNC infusion (5 × 10^7 cells/kg)
Study: 37343576
Drug: Balanced crystalloid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced crystalloid solution (Plasma-Lyte 148)
Study: 34077911
Drug: Informational intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Informational intervention (monthly newsletters about park-based PA opportunities, park program brochures, trail maps, and activity guides)
Study: 36530477
Drug: Trigeminal ganglion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trigeminal ganglion block (2% lidocaine 0.5 mL)
Study: 35499362
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of Epilobium fleischeri extract (twice daily for 4 weeks)
Study: 32758405
Drug: Endorsement of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endorsement of treatment methods
Study: 33957621
Drug: Triamterene 50
Normalized name: triamterene 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triamterene 50 mg twice daily
Study: 35187621
Drug: High-dose ghrelin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ghrelin (0.5 µg/kg/h)
Study: 35187621
Drug: Low-dose ghrelin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ghrelin (0.25 µg/kg/h)
Study: 35187621
Drug: Ghrelin (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ghrelin (both doses)
Study: 36478501
Drug: Tramadol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (100 mg/day, escalated to a maximum of 400 mg/day)
Study: 37084125
Drug: Tight glycemic
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tight glycemic control (80–110 mg/dL)
Study: 37084125
Drug: Moderate glycemic
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate glycemic control (110–140 mg/dL)
Study: 35960115
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ultrasonic debridement and cortex phellodendri compound fluid (CPCF)
Study: 35960115
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ultrasonic debridement and CPCF
Study: 33827990
Drug: AD-203 (rebamipide
Approvals — FDA: no, EMA: no, PMDA: no
Description: AD-203 (rebamipide 150 mg) twice daily for 2 weeks
Study: 33827990
Drug: Mucosta (rebamipide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mucosta (rebamipide 100 mg) thrice daily for 2 weeks
Study: 33827990
Drug: AD-203 (rebamipide
Approvals — FDA: no, EMA: no, PMDA: no
Description: AD-203 (rebamipide 150 mg)
Study: 33827990
Drug: Mucosta (rebamipide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mucosta (rebamipide 100 mg)
Study: 32651644
Drug: Acetaminophen (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (1000 mg) + Codeine (30 mg)
Study: 32651644
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Acetaminophen and Acetaminophen + Codeine)
Study: 32186286
Drug: Regular Platform
Normalized name: Autolet Regular Platform
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular Platform (RP) implants
Study: 32186286
Drug: Platform Switching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platform Switching (PS) implants
Study: 32658610
Drug: udenafil treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: udenafil treatment
Study: 33179377
Drug: Belantamab mafodotin
Normalized name: belantamab mafodotin
DrugBank: Belantamab mafodotin (DB15719)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Belantamab mafodotin 2.5 mg/kg
Study: 33179377
Drug: Belantamab mafodotin
Normalized name: belantamab mafodotin
DrugBank: Belantamab mafodotin (DB15719)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Belantamab mafodotin 3.4 mg/kg
Study: 37061109
Drug: Placebo once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily for 12 months
Study: 35886341
Drug: Iontophoresis with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iontophoresis with Perskindol gel from the positive pole ("+" iontophoresis)
Study: 35886341
Drug: Iontophoresis with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iontophoresis with Perskindol gel from the negative pole ("-" iontophoresis)
Study: 35886341
Drug: Anodic galvanic
Normalized name: OCTINOXATE 0.068 g in 1 g TOPICAL LIPSTICK [ESIKA PRO HD COLOR HIGH DEFINITION COLOR SPF 20 (HD BERRY BALCANIC) - RED]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anodic galvanic treatment
Study: 32443285
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment and prolonged antimicrobial therapy (median duration of antibiotics was 12 weeks)
Study: 33028550
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (single‐pulse TMS to primary motor cortex (M1) above resting motor threshold)
Study: 33028550
Drug: Inactive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive treatment (single‐pulse TMS to M1 below resting motor threshold)
Study: 32761909
Drug: Topical phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical phenytoin (10% phenytoin USP)
Study: 36224325
Drug: Trimetazidine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (20 mg twice a day) in group A (S+)
Study: 36224325
Drug: Trimetazidine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (20 mg twice a day) in group C (S-)
Study: 36344924
Drug: Cisatracurium 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisatracurium 0.15 mg/kg
Study: 35648286
Drug: Second dose
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second dose of immunoglobulin
Study: 35648286
Drug: Eculizumab (monoclonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eculizumab (monoclonal antibody against C5)
Study: 35648286
Drug: ANX005 (humanized
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANX005 (humanized recombinant antibody against C1q)
Study: 32649617
Drug: Prophylactic implantation
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic implantation of a biological intraperitoneal mesh using Strattice (mesh group)
Study: 34045378
Drug: Start antiplatelet
Normalized name: Star Anise Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Start antiplatelet therapy
Study: 32996352
Drug: Schema-enhanced parent
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schema-enhanced parent behavior therapy (SPBT)
Study: 34928302
Drug: mRNA vaccine
Normalized name: RSV mRNA vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA vaccine (BNT162b2 or mRNA‐1273)
Study: 34928302
Drug: Vector vaccine
Normalized name: COVID-19 non-replicating viral vector vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vector vaccine (Ad26COVS1)
Study: 34928302
Drug: Both mRNA
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both mRNA and vector vaccines
Study: 34465677
Drug: Neurodynamics Nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurodynamics Nerve Flossing Technique (NFT) combined with conventional therapy program
Study: 34465677
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy program
Study: 33210773
Drug: Multifactorial intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multifactorial intervention by primary care nurses including motivational interview and individualized prescription of physical activity (150 min/week)
Study: 35343881
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g Egg Protein Hydrolysate (EPH)
Study: 35343881
Drug: 0.5 g
Normalized name: Gelatin Capsules, 10.5 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g Egg Protein Hydrolysate (EPH)
Study: 35343881
Drug: 0.5 g
Normalized name: Gelatin Capsules, 10.5 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g and 1 g Egg Protein Hydrolysate (EPH)
Study: 33184931
Drug: Atrasentan 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrasentan 0.75 mg for 6 weeks
Study: 36476310
Drug: ACME (Antrodia
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACME (Antrodia Cinnamomea mycelia extract) 250 mg daily for 12 weeks
Study: 34126249
Drug: Ranibizumab or
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab or Bevacizumab treatment for neovascular AMD
Study: 32323609
Drug: KP-100 (recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: KP-100 (recombinant human hepatocyte growth factor) administered intrathecally
Study: 34480579
Drug: Zolpidem 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem 30 mg
Study: 33332919
Drug: Phrenic nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phrenic nerve block (PNB) with 10 mL of 0.375% ropivacaine
Study: 39689189
Drug: Half-dose tenecteplase
Normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Half-dose tenecteplase
Study: 33310801
Drug: Fixed-dose antihypertensive
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose antihypertensive monotherapy
Study: 33310801
Drug: Low-dose monotherapy
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose monotherapy (defined daily dose: 0.5 units)
Study: 34134574
Drug: Hyperthermia combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperthermia combined with TPF induction chemotherapy (5-fluorouracil, cisplatin, and docetaxel)
Study: 34134574
Drug: TPF induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPF induction chemotherapy alone
Study: 34134574
Drug: Hyperthermia combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperthermia combined with TPF induction chemotherapy
Study: 35538465
Drug: Self-administered CRAFT
Normalized name: polyvinyl alcohol graft polyethylene glycol copolymer (3:1; 45000 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered CRAFT (control group)
Study: 34971475
Drug: Carboxytherapy at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboxytherapy at a flow rate of 30 ml/min
Study: 34971475
Drug: Carboxytherapy at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboxytherapy at a flow rate of 60 ml/min
Study: 34360315
Drug: ProLiSMental psychoeducational
Approvals — FDA: no, EMA: no, PMDA: no
Description: ProLiSMental psychoeducational intervention (4 or 8 weekly sessions of 90 or 45 min)
Study: 33041022
Drug: HYD diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: HYD diet (75 mg/kg Zn from HYD)
Study: 33041022
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet (75 mg/kg Zn from zinc sulfate)
Study: 33041022
Drug: FR treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: FR treatments (40% of ad libitum feed intake)
Study: 33041022
Drug: AL treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: AL treatments (ad libitum fed)
Study: 35332591
Drug: Intralymphatic immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralymphatic immunotherapy with birch and 5-grass allergen extracts (10,000 SQ units/ml, ALK-Abelló)
Study: 35332591
Drug: Intralymphatic immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralymphatic immunotherapy with birch and placebo
Study: 35332591
Drug: Intralymphatic immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralymphatic immunotherapy with 5-grass and placebo
Study: 33723066
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone gel administration
Study: 33723066
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel administration
Study: 32171667
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (HBOT) - 90 min exposure to 100% O2 at 2 atmospheres absolute, daily for 5 days a week for 4 weeks before surgery and 10 additional sessions after first-stage surgery
Study: 35948268
Drug: n‐3 long‐chain
Approvals — FDA: no, EMA: no, PMDA: no
Description: n‐3 long‐chain polyunsaturated fatty acid supplementation (4.2 g per day)
Study: 34480530
Drug: Preoperative systemic
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative systemic chemotherapy
Study: 33351042
Drug: Digoxin (n=80;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin (n=80; mean dose 161 μg/d)
Study: 33351042
Drug: Bisoprolol (n=80;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol (n=80; mean dose 3.2 mg/d)
Study: 33378384
Drug: High-dose budesonide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose budesonide
Study: 32419128
Drug: Manual chest
Normalized name: Kids-Eeze Chest Relief
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Manual chest compression (CC)
Study: 32694183
Drug: Long-term oxygen
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term oxygen therapy (nasal cannula)
Study: 35607776
Drug: NeuroEPO (nasally
Approvals — FDA: no, EMA: no, PMDA: no
Description: NeuroEPO (nasally administered recombinant EPO)